IntoCell

287840 · KOSDAQ · ₩287840 · 인투셀

₩15,980▼ ₩120 (0.75%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

With these assumptions the model gives no positive value.

Enterprise value
−₩7.9B
Equity value
−₩7.6B
WACC
8.3%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model gives no positive value at these assumptions. What we can see:

  • No operating margin up to 90% gets the model to today's price at these growth assumptions.
  • In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
—
Base
—
Bull
—

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (−20.0%).

Revenue growth

  • -10%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-20.9% a year, annual reports), fading to 3% by year 5.

  • -6.7%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-20.9% a year, annual reports), fading to 3% by year 5.

  • -3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-20.9% a year, annual reports), fading to 3% by year 5.

  • -0.2%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-20.9% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-20.9% a year, annual reports), fading to 3% by year 5.

Business

  • -20%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 39.7%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 49.6%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).

  • 40%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.03%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-27.

  • 0.78

    How much the share moves when the market moves: 1 means just like the market.

    Default: 75 weeks of weekly returns against KOSPI (official index); raw beta 0.67, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.53%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩3.2B
Net debt (borrowings and leases − cash and deposits)
−₩381M
Shares
15,021,960
Share price
₩15,980
Market cap
₩240B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩2.9B₩2.3B₩2.9B₩2.7B₩2.6B₩2.6B₩2.7B
Growth—−20.9%−10.0%−6.7%−3.5%−0.2%3.0%
EBIT−₩9.8B−₩10B−₩575M−₩536M−₩517M−₩516M−₩532M
EBIT margin−337.0%−448.0%−20.0%−20.0%−20.0%−20.0%−20.0%
After-tax EBIT−₩7.1B−₩7.5B−₩417M−₩389M−₩375M−₩374M−₩386M
+ Depreciation——₩1.1B₩1.1B₩1B₩1B₩1.1B
− Capital spending₩1.2B₩1.3B₩1.4B₩1.3B₩1.3B₩1.3B₩1.3B
− Working capital—₩13B−₩128M−₩77M−₩38M−₩2.1M₩31M
Free cash flow——−₩573M−₩577M−₩594M−₩628M−₩680M
Discount factor——0.9230.8520.7870.7260.671
Present value——−₩529M−₩492M−₩467M−₩456M−₩456M

Terminal value −₩8.3B, worth −₩5.5B today: 70% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
7.3%—————
7.8%—————
8.3%—————
8.8%—————
9.3%—————

Now (TTM)

Market cap
₩240B
Enterprise value
₩239B
P/E
—
P/B
12.2×
P/S
75.2×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

2025
Price₩57,400
Market cap₩862B
P/E—
P/B34.8×
P/S375.0×
EV/EBITDA—
Dividend yield0.0%

Loading data for this company — check back soon

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
IntoCell—12.2×75.2×—0.0%
Samsung Biologics32.1×7.6×14.0×—0.0%
Celltrion27.8×2.4×8.9×—0.0%
Alteogen78.8×28.4×59.9×—0.1%
Yuhan24.8×2.5×2.6×32.5×0.8%
SK biopharmaceuticals14.6×5.7×6.8×—0.0%
HLB—15.4×54.6×—0.0%
Similar companies (median)27.8×6.7×11.5×32.5×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: IntoCell / 인투셀 / 287840 / KRX:287840

Source: KRX statistical information